Clinical trials: GERD
Gastro-esophageal Reflux Disease
Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD).
- Trial name
- NCT02114216
- Testing
- endoscopic mucosal biopsy
- Where
- South Korea
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Gastroesophageal Reflux
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
- Trial name
- NCT05343364
- Testing
- Vonoprazan
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
The purpose of this study is to assess the efficacy and safety of rabeprazole 10mg once and twice daily in maintenance therapy for PPI resistant gastroesophageal reflux disease patients.
- Trial name
- NCT02135107
- Testing
- Rabeprazole
- Where
- 61 sites in Japan
- Volunteers
- 517 people
- Sponsor
- Eisai Co., Ltd.
Laryngopharyngeal Reflux, Throat Pain
Anti-reflux Control to Decrease Post Tonsillectomy Pain
The study aims to determine if treating pediatric patients (age 7-17) for four weeks with omeprazole prior to tonsillectomy will decrease post tonsillectomy pain.
- Trial name
- NCT01777854
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Ascension Health
Eosinophilic Esophagitis
Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies
The purpose of this research study is to compare the safety and effectiveness of three commonly used techniques for delivering anesthesia during a procedure known as esophagogastroduodenoscopy.
- Trial name
- NCT02038894
- Testing
- Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Larynx Disease, Gastroesophageal Reflux
Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?
The purpose of the study is to determine if tissue changes are predictor of clinical response to therapy. The hypothesis is that the patients who have laryngeal signs and symptoms related to acid reflux, will have ultrastructural…
- Trial name
- NCT00444145
- Testing
- Prevacid, Esophageal and Laryngeal Biopsies
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Vanderbilt University Medical Center
Gastroparesis, Gastroesophageal Reflux Disease
Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis
The purpose of this study is to compare the blood drug levels of two prescribed medications, immediate-release omeprazole 40 mg powder and delayed-release omeprazole 40 mg capsule to determine which drug is better absorbed in…
- Trial name
- NCT00492622
- Testing
- Immediate-release omeprazole, Delayed-release omeprazole
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Louisville
Healthy Volunteers
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and…
- Trial name
- NCT06831344
- Testing
- Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
GERD
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
- Trial name
- MAESTRO (NCT00444275)
- Testing
- esomeprazole (Nexium®), Xolaam®
- Where
- France
- Volunteers
- 3,029 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, GERD
Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)
The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn
- Trial name
- NCT00373334
- Testing
- nizatidine (axid)
- Where
- 26 sites in United States
- Volunteers
- 138 people
- Sponsor
- Braintree Laboratories
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily [QD]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
- Trial name
- NCT05195528
- Testing
- Vonoprazan
- Where
- 108 sites in United States
- Volunteers
- 776 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease, Heartburn
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
This study is being carried out to see whether AZD3355 is an effective treatment as an add-on to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial response to PPI and to compare this with Proton…
- Conditions
- Gastroesophageal Reflux Disease, Heartburn, Regurgitation
- Trial name
- NCT01005251
- Testing
- lesogaberan (AZD3355)
- Where
- United States
- Volunteers
- 661 people
- Sponsor
- AstraZeneca
Osteoporosis, Achlorhydria
Does Omeprazole Decrease Intestinal Calcium Absorption?
The purpose of this study is to measure the effect of omeprazole on intestinal calcium absorption in postmenopausal women.
- Conditions
- Osteoporosis, Achlorhydria, GERD, Hip Fracture
- Trial name
- NCT00582972
- Testing
- Omeprazole
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive…
- Trial name
- NCT00838526
- Testing
- Rabeprazole ER, Ranitidine
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Barrett's Esophagus
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of…
- Trial name
- NCT01298999
- Testing
- YF476
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Columbia University
Gastroesophageal Reflux
Implementation of PPI Medication PGX Testing
Using genetic information about the individual to pick the right drug for the right disease at the right dose defines personalized medicine.
- Trial name
- PGX (NCT02794844)
- Testing
- Genotype Guided PPI Dosing
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nemours Children's Clinic
Gastroesophageal Reflux Disease
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent…
- Trial name
- NCT01472939
- Testing
- SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI
- Where
- 88 sites in United States, Czechia and 4 more
- Volunteers
- 480 people
- Sponsor
- Shire
Gastro-oesophageal Reflux Disease
Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor
The aim of the present study was to evaluate the effect of a 6-weeks treatment of a CE-marked combination oral formulation of hyaluronic acid with chondroitin sulphate and aluminium hydroxide (GERDOFF®), in addition to proton…
- Trial name
- NCT03793556
- Testing
- GERDOFF® + Omeprazole, Omeprazole
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- SOFAR S.p.A.
Gastroesophageal Reflux Disease
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NEON (NCT00734097)
- Testing
- Esomeprazole 40 mg, Physical Exam, Quality of Life Questionnaires
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca